<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261129</url>
  </required_header>
  <id_info>
    <org_study_id>502.557</org_study_id>
    <nct_id>NCT02261129</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers</brief_title>
  <official_title>Bioequivalence of the 80 mg Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional 40 mg Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to demonstrate the bioequivalence of the telmisartan 80 mg film-coated tablet vs. two
      tablets of the telmisartan 40 mg conventional tablet
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to last quantifiable data point (AUC0-tz)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum measured concentration of the analyte in plasma (tmax)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant of the analyte in plasma (λz)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean residence time of the analyte in the body after po administration (MRTpo)</measure>
    <time_frame>up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 72 hours after last drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telmisartan, film-coated tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one tablet of telmisartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan, conventional tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two tablets of telmisartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan film-coated tablet</intervention_name>
    <arm_group_label>Telmisartan, film-coated tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan uncoated tablet</intervention_name>
    <arm_group_label>Telmisartan, conventional tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Japanese males according to the following criteria:

             Based upon a complete medical history, including the physical examination, vital signs
             (Blood pressure, pulse rate, body temperature), 12-lead ECG, clinical laboratory tests

               -  1.1 No findings deviating from normal and of clinical relevance

               -  1.2 No evidence of a clinically relevant concomitant disease

          2. Age ≥20 and ≤35 years

          3. Body weight≥50kg

          4. Body Mass Index ≥18.0 and ≤25.0 kg/m2

          5. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation

        Exclusion Criteria:

          1. Any finding of the medical examination (including blood pressure, pulse rate, body
             temperature, and ECG) deviating from normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, or hormonal disorders

          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          5. Chronic or relevant acute infections

          6. History of relevant allergy/hypersensitivity (including allergy to a drug or its
             excipients)

          7. Any clinical relevant findings of the laboratory test deviating from normal

          8. Positive result for either hepatitis B antigen, anti hepatitis C virus antibodies,
             syphilitic test or human immunodeficiency virus (HIV) test

          9. History of surgery of gastrointestinal tract (except appendectomy)

         10. History of relevant orthostatic hypotension (mean standing systolic blood pressure
             (SBP) varies by ≥20 mmHg from mean supine SBP or mean standing diastolic blood
             pressure (DBP) varies by ≥10 mmHg from mean supine DBP), fainting spells or blackouts

         11. History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis)

         12. History of serious renal dysfunction

         13. History of bilateral renal artery stenosis or renal artery stenosis in a solitary
             kidney

         14. History of cerebrovascular disorder

         15. History of hyperkalemia

         16. Known hypersensitivity to any component of the telmisartan formulation, or to any
             other angiotensin II receptor blockers

         17. Intake of drugs with a long half-life (≥24 hours) within at least one month or less
             than 10 half-lives of the respective drug before administration of the investigational
             product

         18. Use of any drugs within 10 days before administration of the investigational product
             or during the trial

         19. Participation in another trial with an investigational drug within four months before
             administration of the investigational product or during the trial

         20. Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day)

         21. Alcohol abuse

         22. Drug abuse

         23. Blood donation (100 mL or more) within four weeks before administration of the
             investigational product

         24. Excessive physical activities within one week before administration of the
             investigational product or during the trial

         25. Intake of alcohol within 2 days prior to administration

         26. Inability to comply with dietary regimen of study centre

         27. Inability to refrain from smoking on trial days

         28. Any other clinical conditions that investigator or sub-investigator judges that the
             subject is ineligible for study participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

